Bicara Therapeutics (NASDAQ:BCAX) COO Ryan Cohlhepp Sells 18,750 Shares of Stock

Bicara Therapeutics Inc. (NASDAQ:BCAX) COO Ryan Cohlhepp sold 18,750 shares of the company’s stock in a transaction on Monday, August 10th. The stock was sold at an average price of $27.98, for a total transaction of $524,625.00. Following the transaction, the chief operating officer directly owned 181,641 shares in the company, valued at approximately $5,082,315.18. This trade represents a 9.36% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through the SEC website. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan.

Ryan Cohlhepp also recently made the following trade(s):

• On Thursday, July 9th, Ryan Cohlhepp sold 536 shares of Bicara Therapeutics stock. The shares were sold at an average price of $29.00, for a total transaction of $15,544.00.
• On Wednesday, July 8th, Ryan Cohlhepp sold 28,214 shares of Bicara Therapeutics stock. The stock was sold at an average price of $28.98, for a total value of $817,641.72.
• On Friday, May 15th, Ryan Cohlhepp sold 12,500 shares of Bicara Therapeutics stock. The stock was sold at an average price of $20.29, for a total value of $253,625.00.

Bicara Therapeutics Stock Up 3.7%

NASDAQ BCAX traded up $0.87 during mid-day trading on Wednesday, hitting $24.63. The stock had a trading volume of 810,259 shares, compared to its average volume of 608,476. The company has a 50 day simple moving average of $25.90 and a 200 day simple moving average of $21.69. The company has a market cap of $1.62 billion, a price-to-earnings ratio of -8.86 and a beta of -0.75. Bicara Therapeutics Inc. has a 52-week low of $10.30 and a 52-week high of $30.99.

Bicara Therapeutics (NASDAQ:BCAX) last posted its earnings results on Tuesday, August 11th. The company reported ($0.82) EPS for the quarter, hitting analysts’ consensus estimates of ($0.82). As a group, equities analysts anticipate that Bicara Therapeutics Inc. will post -3.42 earnings per share for the current fiscal year.

Bicara Therapeutics News Roundup

Here are the key news stories impacting Bicara Therapeutics this week:

• Positive Sentiment: Bicara reported a second-quarter loss of $0.82 per share, described as narrower than expected and matching the cited analyst consensus. The result helped support the view that the company is maintaining financial discipline while advancing its pipeline. Bicara Therapeutics Analysts Raise Their Forecasts After Q2 Results
• Positive Sentiment: The company said enrollment in its pivotal cancer study is progressing and remains on track for completion in 2026. Wedbush viewed the enrollment timeline as a positive catalyst for BCAX’s clinical program. Bicara Therapeutics’ Cancer Study On Track for 2026 Enrollment, Wedbush Says
• Positive Sentiment: BTIG Research raised its price target from $28 to $39 and maintained a Buy rating, implying substantial potential upside based on expectations for Bicara’s clinical and commercial prospects. Benzinga
• Positive Sentiment: Recent commentary remains constructive despite broader market headwinds, with optimism centered on the company’s pipeline progress and upcoming clinical milestones. Bicara Therapeutics: My Optimism Is Building Despite Recent Market Headwinds
• Neutral Sentiment: Bicara also announced strategic leadership transitions intended to support its next phase of execution and growth. The changes may improve operational focus, but they introduce an element of transition risk. Bicara Therapeutics Reports Second Quarter 2026 Progress
• Negative Sentiment: Wells Fargo raised its price target from $16 to $23 but retained an Equal Weight rating. Its target remains below the referenced trading level, signaling a more cautious view than BTIG’s forecast. Benzinga

Institutional Trading of Bicara Therapeutics

A number of hedge funds have recently bought and sold shares of BCAX. Siren L.L.C. lifted its stake in shares of Bicara Therapeutics by 11.2% during the 1st quarter. Siren L.L.C. now owns 5,802,970 shares of the company’s stock worth $115,421,000 after purchasing an additional 586,001 shares during the period. Vestal Point Capital LP increased its stake in Bicara Therapeutics by 2.0% in the third quarter. Vestal Point Capital LP now owns 5,100,000 shares of the company’s stock valued at $80,529,000 after purchasing an additional 100,000 shares during the last quarter. BlackRock Inc. acquired a new position in Bicara Therapeutics in the second quarter valued at $114,250,000. Janus Henderson Group PLC lifted its position in Bicara Therapeutics by 26.2% during the first quarter. Janus Henderson Group PLC now owns 3,339,218 shares of the company’s stock worth $66,350,000 after buying an additional 692,933 shares during the period. Finally, T. Rowe Price Investment Management Inc. lifted its position in Bicara Therapeutics by 596.5% during the fourth quarter. T. Rowe Price Investment Management Inc. now owns 3,236,595 shares of the company’s stock worth $54,472,000 after buying an additional 2,771,868 shares during the period.

Analyst Ratings Changes

A number of equities analysts have issued reports on BCAX shares. Cantor Fitzgerald restated an “overweight” rating on shares of Bicara Therapeutics in a research report on Wednesday, May 27th. Wall Street Zen raised shares of Bicara Therapeutics from a “strong sell” rating to a “sell” rating in a research note on Sunday, May 24th. Wells Fargo & Company lifted their price objective on Bicara Therapeutics from $16.00 to $23.00 and gave the stock an “equal weight” rating in a research report on Wednesday. Morgan Stanley upped their target price on Bicara Therapeutics from $37.00 to $39.00 and gave the company an “overweight” rating in a research note on Tuesday. Finally, Guggenheim initiated coverage on Bicara Therapeutics in a report on Monday, May 11th. They set a “buy” rating and a $42.00 target price on the stock. One research analyst has rated the stock with a Strong Buy rating, ten have assigned a Buy rating, three have issued a Hold rating and one has given a Sell rating to the company’s stock. Based on data from MarketBeat, the company has a consensus rating of “Moderate Buy” and a consensus target price of $32.73.

Bicara Therapeutics Company Profile

Bicara Therapeutics is a clinical-stage biopharmaceutical company dedicated to developing novel neurohormone-based therapies for psychiatric and neurological disorders. The company’s research focuses on harnessing endogenous signaling pathways in the brain, with the goal of offering new treatment options for conditions that remain inadequately addressed by existing medications. Bicara applies proprietary peptide engineering and intranasal delivery platforms to optimize central nervous system uptake and therapeutic effect.

The company’s lead candidates include PST-001, an intranasal vasopressin-1A receptor antagonist in development for postpartum depression, and PST-002, an oxytocin receptor modulator being investigated for social anxiety and autism spectrum disorder.